Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy.
As the first earnings season of 2025 unfolds, investors are likely analyzing financial reports to refine their portfolio strategies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback